INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...
Xue-Mei Zeng, Nicholas Heaton, Rebecca A. Deek et al.· medRxiv· 0 citations
Objective: Late-life depression (LLD) increases dementia risk, emphasizing the potential and importance of lifestyle interventions to support cognition. However, no biomarker-based models currently exist to predict their effectiveness. We examined whether plasma Alzheimer’s disease and related dementia (ADRD) biomark...
Keeley M. Scullin, A. P. Costa, Amrita Sahu et al.· Archives of Clinical Neurops...· 0 citations
Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologi...
R. Shi, X. Zeng, M. Farinas et al.· medRxiv· 0 citations
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder strongly influenced by genetic factors, with apolipoprotein E (APOE) {epsilon}4 allele being the most established risk variant. Although DNA-based genotyping remains standard, plasma proteotyping may provide scalable, isoform-specific alternat...
Ru-Yu Shi, L. Choity, M. Farinas et al.· medRxiv· 0 citations
Current biobanking guidelines require in-person blood collection and immediate processing for Alzheimer's disease (AD) biomarker assessment. We recently reported that the P100 blood collection tubes containing protease inhibitors improve protein biomarker stability over delayed centrifugation periods. However, whether...
Yron K. Lee, X. Zeng, M. Farinas et al.· medRxiv· 0 citations
These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.
R. Shi, L. Choity, S. Brodman et al.· medRxiv· 0 citations